Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CCDC6 (Coiled-Coil Domain Containing 6)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	RET inhibitor Sensitive: C3 – Early Trials RET inhibitor Sensitive : C3	RET inhibitor Sensitive: C3 – Early Trials RET inhibitor Sensitive : C3
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
CCDC6-RET fusion	Colorectal Cancer	CCDC6-RET fusion	Colorectal Cancer	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3	cabozantinib capsule Sensitive: C3 – Early Trials cabozantinib capsule Sensitive : C3
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3
PD-L1 overexpression + RET-CCDC6 fusion	Non Small Cell Lung Cancer	PD-L1 overexpression + RET-CCDC6 fusion	Non Small Cell Lung Cancer	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4
RET G810C + CCDC6-RET fusion	Non Small Cell Lung Cancer	RET G810C + CCDC6-RET fusion	Non Small Cell Lung Cancer	selpercatinib Resistant: C4 – Case Studies selpercatinib Resistant : C4	selpercatinib Resistant: C4 – Case Studies selpercatinib Resistant : C4
CCDC6-RET fusion	Thyroid Gland Anaplastic Carcinoma	CCDC6-RET fusion	Thyroid Gland Anaplastic Carcinoma	selpercatinib Sensitive: C4 – Case Studies selpercatinib Sensitive : C4	selpercatinib Sensitive: C4 – Case Studies selpercatinib Sensitive : C4